KDM6A and hepatocellular carcinoma: As drug response is closely associated with the survival outcome of patients with HCC, our results indicate that KDM6A is an important new molecule affecting the efficacy of lenvatinib in HCC therapy and identify that patients who suffer from HCC with a high KDM6A level are more suitable for lenvatinib therapy.